Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(24):1825; doi:10.1093/jnci/94.24.1825
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 24, 1825, December 18, 2002
© 2002 Oxford University Press

NEWS

Preliminary Findings of the Oversight and Investigations Subcommittee

The first 10% of the full text of this article appears below.

Selected findings from the committee’s preliminary report on the development of the drug Erbitux by ImClone Systems Inc.:

• In . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?